Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mirco Pistelli

Showing results (1-10 of 55) with videos related to

Pageof 6
Sort By:
Cancer Treatment Reviews|September 2, 2017
Healthcare cost of HER2-positive and negative breast tumors in the United States (2012-2035)Francesca Tartari, Matteo Santoni, Mirco Pistelli, et al.
Tumori|July 27, 2011
Second-line chemotherapy with irinotecan, 5-fluorouracil and leucovorin (FOLFIRI) in relapsed or metastatic gastric cancer: lessons from clinical practiceMirco Pistelli, Mario Scartozzi, Alessandro Bittoni, et al.
World Journal of Surgical Oncology|December 18, 2014
Metastatic breast cancer mimicking a hilar cholangiocarcinoma: case report and review of the literatureMartina Coletta, Roberto Montalti, Mirco Pistelli, et al.
Core Evidence|November 3, 2010
Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancerRossana Berardi, Azzurra Onofri, Mirco Pistelli, et al.
Anticancer Research|June 11, 2013
Prognostic factors in early-stage triple-negative breast cancer: lessons and limits from clinical practiceMirco Pistelli, Alessandra Pagliacci, Nicola Battelli, et al.
Current Oncology (Toronto, Ont.)|April 25, 2025
New Therapeutic Scenarios in the Context of Adjuvant Treatment for HR+/HER2-Breast Cancer: The Possible Role of Ribociclib in Treatment Algorithms for Stage II and IIINicola Battelli, Carmela Mocerino, Michele Montedoro, et al.
Cancer Treatment Reviews|May 27, 2009
Toward molecularly selected chemotherapy for advanced gastric cancer: state of the art and future perspectivesMario Scartozzi, Alessandro Bittoni, Mirco Pistelli, et al.
Molecular and Clinical Oncology|February 2, 2018
Long-responders to anti-HER2 therapies: A case report and review of the literatureLuca Cantini, Mirco Pistelli, Agnese Savini, et al.
Springerplus|December 23, 2015
Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysisAlessandro Bittoni, Michela Del Prete, Mario Scartozzi, et al.
La Radiologia Medica|June 6, 2018
Role of DCE-MR in predicting breast cancer subtypesMarco Macchini, Martina Ponziani, Andrea Prochowski Iamurri, et al.
Pageof 6

Showing results (1-10 of 55) with videos related to

Sort By:
Pageof 6
Cancer Treatment Reviews|September 2, 2017
Healthcare cost of HER2-positive and negative breast tumors in the United States (2012-2035)Francesca Tartari, Matteo Santoni, Mirco Pistelli, et al.
Tumori|July 27, 2011
Second-line chemotherapy with irinotecan, 5-fluorouracil and leucovorin (FOLFIRI) in relapsed or metastatic gastric cancer: lessons from clinical practiceMirco Pistelli, Mario Scartozzi, Alessandro Bittoni, et al.
World Journal of Surgical Oncology|December 18, 2014
Metastatic breast cancer mimicking a hilar cholangiocarcinoma: case report and review of the literatureMartina Coletta, Roberto Montalti, Mirco Pistelli, et al.
Core Evidence|November 3, 2010
Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancerRossana Berardi, Azzurra Onofri, Mirco Pistelli, et al.
Anticancer Research|June 11, 2013
Prognostic factors in early-stage triple-negative breast cancer: lessons and limits from clinical practiceMirco Pistelli, Alessandra Pagliacci, Nicola Battelli, et al.
Current Oncology (Toronto, Ont.)|April 25, 2025
New Therapeutic Scenarios in the Context of Adjuvant Treatment for HR+/HER2-Breast Cancer: The Possible Role of Ribociclib in Treatment Algorithms for Stage II and IIINicola Battelli, Carmela Mocerino, Michele Montedoro, et al.
Cancer Treatment Reviews|May 27, 2009
Toward molecularly selected chemotherapy for advanced gastric cancer: state of the art and future perspectivesMario Scartozzi, Alessandro Bittoni, Mirco Pistelli, et al.
Molecular and Clinical Oncology|February 2, 2018
Long-responders to anti-HER2 therapies: A case report and review of the literatureLuca Cantini, Mirco Pistelli, Agnese Savini, et al.
Springerplus|December 23, 2015
Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysisAlessandro Bittoni, Michela Del Prete, Mario Scartozzi, et al.
La Radiologia Medica|June 6, 2018
Role of DCE-MR in predicting breast cancer subtypesMarco Macchini, Martina Ponziani, Andrea Prochowski Iamurri, et al.
Pageof 6